Data as of 11:31am ET
| 0.00 / 0.00%|
The 2 analysts offering 12-month price forecasts for Transition Therapeutics Inc have a median target of 4.41, with a high estimate of 4.53 and a low estimate of 4.29. The median estimate represents a -23.51% decrease from the last price of 5.77.
The current consensus among 2 polled investment analysts is to Hold stock in Transition Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.